113 related articles for article (PubMed ID: 17346275)
1. Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon-alpha.
Yang JL; Qu XJ; Hayes VM; Brenner PC; Russell PJ; Goldstein D
BJU Int; 2007 Jun; 99(6):1539-45. PubMed ID: 17346275
[TBL] [Abstract][Full Text] [Related]
2. Interferon-alpha promotes the anti-proliferative effect of Erlotinib (OSI-774) on human colon cancer cell lines.
Yang JL; Qu XJ; Russell PJ; Goldstein D
Cancer Lett; 2005 Jul; 225(1):61-74. PubMed ID: 15922858
[TBL] [Abstract][Full Text] [Related]
3. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
[TBL] [Abstract][Full Text] [Related]
4. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
5. Interferon-alpha promotes the anti-proliferative effect of gefitinib (ZD 1839) on human colon cancer cell lines.
Yang JL; Qu XJ; Russell PJ; Goldstein D
Oncology; 2005; 69(3):224-38. PubMed ID: 16138001
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor status and the response of bladder carcinoma cells to erlotinib.
Jacobs MA; Wotkowicz C; Baumgart ED; Neto BS; Rieger-Christ KM; Bernier T; Cohen MS; Libertino JA; Summerhayes IC
J Urol; 2007 Oct; 178(4 Pt 1):1510-4. PubMed ID: 17707060
[TBL] [Abstract][Full Text] [Related]
7. Correlation of HER1/EGFR expression and degree of radiosensitizing effect of the HER1/EGFR-tyrosine kinase inhibitor erlotinib.
Kim JC; Ali MA; Nandi A; Mukhopadhyay P; Choy H; Cao C; Saha D
Indian J Biochem Biophys; 2005 Dec; 42(6):358-65. PubMed ID: 16955736
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
10. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
Wiedmann M; Feisthammel J; Blüthner T; Tannapfel A; Kamenz T; Kluge A; Mössner J; Caca K
Anticancer Drugs; 2006 Aug; 17(7):783-95. PubMed ID: 16926628
[TBL] [Abstract][Full Text] [Related]
11. Changes in epidermal growth factor receptor expression in human bladder cancer cell lines following interferon-alpha treatment.
Qu XJ; Yang JL; Russell PJ; Goldstein D
J Urol; 2004 Aug; 172(2):733-8. PubMed ID: 15247772
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
Chinnaiyan P; Huang S; Vallabhaneni G; Armstrong E; Varambally S; Tomlins SA; Chinnaiyan AM; Harari PM
Cancer Res; 2005 Apr; 65(8):3328-35. PubMed ID: 15833866
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.
Van Schaeybroeck S; Karaiskou-McCaul A; Kelly D; Longley D; Galligan L; Van Cutsem E; Johnston P
Clin Cancer Res; 2005 Oct; 11(20):7480-9. PubMed ID: 16243822
[TBL] [Abstract][Full Text] [Related]
14. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
15. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.
Blehm KN; Spiess PE; Bondaruk JE; Dujka ME; Villares GJ; Zhao YJ; Bogler O; Aldape KD; Grossman HB; Adam L; McConkey DJ; Czerniak BA; Dinney CP; Bar-Eli M
Clin Cancer Res; 2006 Aug; 12(15):4671-7. PubMed ID: 16899617
[TBL] [Abstract][Full Text] [Related]
16. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
[TBL] [Abstract][Full Text] [Related]
17. Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression.
Schaefer G; Shao L; Totpal K; Akita RW
Cancer Res; 2007 Feb; 67(3):1228-38. PubMed ID: 17283159
[TBL] [Abstract][Full Text] [Related]
18. Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.
Choi YJ; Rho JK; Jeon BS; Choi SJ; Park SC; Lee SS; Kim HR; Kim CH; Lee JC
Cancer Chemother Pharmacol; 2010 Jul; 66(2):381-8. PubMed ID: 19921194
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib antitumor activity in non-small cell lung cancer models is independent of HER1 and HER2 overexpression.
Friess T; Scheuer W; Hasmann M
Anticancer Res; 2006; 26(5A):3505-12. PubMed ID: 17094474
[TBL] [Abstract][Full Text] [Related]
20. Implications of EGFR inhibition in ovarian cancer cell proliferation.
Bull Phelps SL; Schorge JO; Peyton MJ; Shigematsu H; Xiang LL; Miller DS; Lea JS
Gynecol Oncol; 2008 Jun; 109(3):411-7. PubMed ID: 18423824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
